Genetic Familial Hypercholesterolaemia Risk
Private Familial Hypercholesterolaemia genetic test in London for £600, analysing five genes with results expected in around 4–6 weeks.
Turnaround time
4-6 weeks
Biomarkers count
5
Book your test
Choose Service Type
Professional phlebotomist comes to you
+ £{{ home_visit_fee }}
Visit our clinic for your test
{{ clinic_visit_fee > 0 ? '+ £' + clinic_visit_fee : 'Free' }}
Home Visit Details
Home visits require at least 24 hours notice.
Select a clinic: Sorting by distance…
{{ clinicAddress(clinic) }}
{{ clinicAddress(selectedClinic) }}
Select a date
Select an hour
Available time slots: {{ timeSlots.length}}
Overview of the Genetic Familial Hypercholesterolaemia Risk
The Genetic Familial Hypercholesterolaemia Risk test is a five-gene genetic panel designed to identify inherited variants associated with Familial Hypercholesterolaemia and abnormal cholesterol metabolism.
The test contains 5 genetic biomarkers: ApoB, APOE, LDLR, LDLRAP1 and PCSK9.
Familial Hypercholesterolaemia, commonly abbreviated to FH, is an inherited condition associated with substantially elevated LDL Cholesterol from a young age.
Because LDL exposure is increased over many decades, untreated FH can significantly increase the risk of premature coronary artery disease.
The LDLR gene is one of the principal genes associated with monogenic Familial Hypercholesterolaemia because it encodes the LDL receptor responsible for clearing LDL particles from the bloodstream.
Variants affecting ApoB can interfere with the interaction between LDL particles and LDL receptors.
Certain PCSK9 variants can reduce the number of functional LDL receptors available on liver cells and increase circulating LDL.
LDLRAP1 is associated with an autosomal recessive inherited hypercholesterolaemia syndrome.
APOE plays an important role in lipoprotein transport and metabolism and can provide additional lipid-related genetic information.
A genetic result should always be interpreted alongside actual cholesterol measurements and family history.
A negative genetic test does not completely exclude a clinical diagnosis of Familial Hypercholesterolaemia, because not every inherited cause is necessarily identified by one panel.
Likewise, not every genetic change found is automatically disease-causing. Genetic variants are classified according to available evidence.
What Does the Genetic Familial Hypercholesterolaemia Risk Test Check?
The panel analyses five genes involved in cholesterol transport, LDL-receptor activity and inherited lipid metabolism to look for genetic variants that may contribute to Familial Hypercholesterolaemia. This test measures 5 genetic biomarkers.
ApoB
Analyses genetic variation affecting Apolipoprotein B, a structural protein of LDL-containing particles involved in receptor binding and cholesterol transport.
APOE
Analyses genetic variation within APOE, a gene involved in lipid transport and lipoprotein clearance.
LDLR
Analyses the LDL receptor gene, one of the principal genes associated with monogenic Familial Hypercholesterolaemia.
LDLRAP1
Analyses a gene involved in normal LDL-receptor internalisation and associated with autosomal recessive hypercholesterolaemia.
PCSK9
Analyses a gene regulating LDL-receptor availability; selected variants can increase LDL Cholesterol significantly.
Who May Benefit From the Genetic Familial Hypercholesterolaemia Risk Test?
Genetic testing may be particularly useful when cholesterol concentrations and family history suggest that high LDL could have a strong inherited component.
People with very high LDL Cholesterol from a young age - Marked persistent elevation can raise suspicion of Familial Hypercholesterolaemia.
People with a strong family history of premature coronary heart disease - Early heart attacks or coronary disease within a family can indicate inherited cardiovascular risk.
People with a first-degree relative diagnosed with Familial Hypercholesterolaemia - Genetic testing can help establish whether an inherited variant has been shared.
People with persistently high cholesterol despite a healthy lifestyle - Genetic factors can be important even when diet, weight and exercise are favourable.
People whose clinical FH diagnosis remains uncertain - Genetic evidence can provide additional information alongside cholesterol and family history.
Families in which an FH-associated variant has already been identified - Genetic cascade testing can identify relatives who carry the same familial variant.
People who developed cardiovascular disease unusually young and also have high LDL - An inherited lipid disorder may contribute to cumulative cardiovascular risk.
How to Prepare
Because this is a DNA test, fasting, diet and cholesterol treatment do not alter the underlying genetic result, although clinical and family information remains important for interpretation.
There is no need to stop lipid-lowering medication or deliberately increase cholesterol intake before genetic testing.
Your inherited DNA remains the same regardless of current treatment or diet.
Symptoms and Reasons to Consider the Genetic Familial Hypercholesterolaemia Risk Test
Familial Hypercholesterolaemia usually causes no symptoms from the cholesterol itself, making family history and repeated lipid measurements particularly important.
Very high LDL Cholesterol on repeated blood tests - Persistent marked LDL elevation is the principal biochemical clue to FH.
A parent, sibling or child diagnosed with Familial Hypercholesterolaemia - FH is inherited and can affect multiple family members.
Heart attack or coronary artery disease occurring unusually young in close relatives - Premature cardiovascular disease is an important warning sign.
Tendon xanthomata - Cholesterol deposits within tendons can occur in some people with longstanding FH.
High cholesterol despite healthy weight and lifestyle - An inherited mechanism can remain important even when lifestyle risk factors are limited.
A family member with a known pathogenic LDLR, APOB, PCSK9 or related variant - Testing may clarify whether the same genetic risk has been inherited.
Do not wait for cardiovascular symptoms before addressing markedly elevated LDL Cholesterol.
The principal risk in Familial Hypercholesterolaemia comes from cumulative LDL exposure over many years, so early diagnosis and appropriate treatment can be important.
How to Book Your Genetic Familial Hypercholesterolaemia Risk Test
The genetic FH panel can be booked privately for people who want to investigate whether persistent high cholesterol may have an identifiable inherited cause.
Choose the Genetic Familial Hypercholesterolaemia Risk
Select the five-gene genetic panel online.
Select your sample collection option
Choose an appropriate in-clinic or professional home collection pathway.
Attend your appointment
The required sample is collected for molecular genetic analysis.
Laboratory analysis
ApoB, APOE, LDLR, LDLRAP1 and PCSK9 are analysed and detected variants undergo classification.
Receive your results securely
Your authorised genetic report is delivered securely and can be reviewed with an appropriate clinician or genetic professional.
When Will I Receive My Results?
The current expected turnaround for the Genetic Familial Hypercholesterolaemia Risk test is approximately 4–6 weeks after your sample reaches the laboratory.
Genetic testing takes considerably longer than a routine cholesterol blood test because DNA must be processed, analysed and reviewed.
Where a variant is identified, the laboratory must evaluate whether available evidence supports classification as pathogenic, likely pathogenic, uncertain, likely benign or benign.
This interpretative process forms part of the laboratory turnaround.
Occasionally, a rare or technically complex finding can require additional review and may extend the reporting period.
Understanding Your Results
Genetic results should be interpreted according to both the variant classification and the individual's cholesterol and family history.
A pathogenic or likely pathogenic variant in an FH-associated gene can provide strong genetic evidence for an inherited lipid disorder.
A negative result means that no relevant reportable variant was identified within the genes and regions analysed.
It does not completely exclude Familial Hypercholesterolaemia, particularly where LDL Cholesterol and family history strongly support a clinical diagnosis.
A Variant of Uncertain Significance, or VUS, means current scientific evidence is insufficient to determine whether the genetic change causes disease.
A VUS should not automatically be treated as a confirmed positive FH result.
A confirmed inherited variant may also have implications for biological relatives because parents, siblings and children may carry the same genetic change.
Results should therefore be interpreted alongside actual LDL Cholesterol, age, treatment history and family cardiovascular history.
Why Book With London Blood Tests?
This genetic test provides information about inherited cholesterol risk that cannot be obtained from a routine lipid profile alone.
Five-gene genetic analysis - ApoB, APOE, LDLR, LDLRAP1 and PCSK9 are assessed.
Relevant to Familial Hypercholesterolaemia - Genetic evidence can support an inherited cause of markedly elevated LDL.
Lifetime genetic result - Your inherited DNA does not change with age.
Useful for family risk assessment - A confirmed familial variant can support cascade testing of biological relatives.
Not affected by statins - Lipid-lowering treatment does not alter the genetic result.
No fasting required - Recent food intake does not affect the DNA analysis.
Specialist genetic laboratory analysis - Detected variants undergo molecular and clinical classification.
Secure reporting - Receive your authorised genetic report confidentially.
Clear pricing - The Genetic Familial Hypercholesterolaemia Risk test costs £600.
Private Genetic Familial Hypercholesterolaemia Risk Test in London
London Blood Tests provides private Genetic Familial Hypercholesterolaemia Risk testing for people seeking information about inherited causes of very high cholesterol.
The test costs £600 and analyses 5 genetic biomarkers.
Results are expected approximately 4–6 weeks after laboratory receipt.
The genetic result should be interpreted alongside a current lipid profile and family history because a negative panel does not completely exclude clinically diagnosed Familial Hypercholesterolaemia.